BCR–ABL halving time indicates CML prognosis during front-line TKI

Calculating halving time of the BCR–ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia patients undergoing first-line tyrosine kinase inhibitor therapy, say researchers.
Source: MedWire News - Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news